MALVERN, Pa., Oct. 23, 2018 /PRNewswire/ -- Ocugen, Inc., a clinical stage biopharmaceutical company focused on discovering, developing and commercializing a pipeline of innovative therapies that address rare and underserved eye diseases, today announced that an abstract describing the Phase 2 clinical study results for OCU310, the Company's lead drug candidate for Dry Eye Disease (DED) has been accepted for a poster presentation at the 2018 Annual Meeting of The American Academy of Ophthalmology (AAO), taking place October 27-30, at McCormick Place in Chicago.
The poster will highlight the tolerability and preliminary efficacy results from a randomized Phase 2 proof-of-concept study in patients with DED. Based on these results and a completed End of Phase 2 meeting with the FDA, Ocugen initiated a Phase 3 clinical study for OCU310 at the end of the third quarter.
Poster and Presentation Details:
A Phase 2 Randomized, Placebo-Controlled, Double-Masked, Proof-of-Concept Study of Brimonidine (BRI) Eye Drops for the Treatment of Dry Eye Disease (DED)
Daniel Jorgensen, MD, MPH; Nicole Zangler, OD; Parag A. Majmudar, MD
Session Two; South Hall A; October 29 (7am-5pm CT) – October 30 (7am-1pm CT)
Monday, October 29, 12:45pm – 1:45pm CT
About Ocugen, Inc.
Ocugen, Inc., is a clinical stage biopharmaceutical company focused on discovering, developing and commercializing a pipeline of innovative therapies that address rare and underserved eye diseases. The Company's lead clinical candidate (OCU300) is currently in Phase 3 for patients with ocular graft versus host disease (oGVHD) and is the first and only therapeutic with orphan drug designation for oGVHD, providing certain regulatory and economic benefits. The Company's second lead candidate (OCU310) is also in Phase 3 for patients with dry eye disease. Both OCU300 and OCU310 leverage Ocugen's patented OcuNanoE – Ocugen's ONE Platform™ technology to enhance the efficacy of topical ophthalmic therapeutics. Ocugen is also developing novel biologic therapies for retinitis pigmentosa (OCU100) and wet AMD (OCU200), as well as a groundbreaking modifier gene therapy platform with potential to address a broad spectrum of inherited retinal disorders (OCU400). For more information, please visit www.ocugen.com.
SOURCE Ocugen, Inc.